Dr Mukesh Chandra SHarma

@dauniv.ac.in

School of Pharmacy, Devi Ahilya University, Indore (M.P)-452 001 India
School of Pharmacy, Devi Ahilya University, Indore (M.P)-452 001 India



              

https://researchid.co/m.c.sharma

RESEARCH, TEACHING, or OTHER INTERESTS

Drug Discovery, Organic Chemistry, General Pharmacology, Toxicology and Pharmaceutics, Analytical Chemistry

195

Scopus Publications

Scopus Publications

  • Polymer mediated light responsive therapeutics delivery system to treat cancer
    Devesh Kapoor, Neha Maheshwari, Anindita Bag, Mukesh C. Sharma, Bhupendra Prajapati, and Rahul Maheshwari
    Elsevier BV

  • Metallic nanoparticles in cancer: Types, green synthesis, applications, tumor microenvironment and toxicity considerations
    Devesh Kapoor, Neha Maheshwari, Namrita Soni, Nidhi Jain Singhai, Mukesh C. Sharma, Bhupendra Prajapati, Santosh Yele, and Rahul Maheshwari
    Elsevier BV

  • Photoresponsive 'chemo-free' phytotherapy: formulation development for the treatment of triple-negative breast cancer
    Neha Maheshwari and Mukesh C Sharma
    Informa UK Limited
    Aim: The present investigation aimed to develop a chemo-free, nanophytosomal system to treat triple-negative breast cancer (TNBC) via a phyto–photo dual treatment strategy. Method: Size, shape, surface analysis, photoprovoked release profile, photothermal stability, (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay, apoptotic assay, DNA fragmentation, in vitro cellular uptake evaluation, mitochondrial membrane potential and caspase-3 assay, and photodynamic evaluation. Results: Biological experiments using MDA-MB-231 cells displayed dose-dependent synergistic anti-TNBC activity of PhytoS/ Houttuynia cordata extract (HCE)/IR780 as compared with Phyto/HCE, PhytoS/IR780 and even more promising under laser treatment. Apoptotic assay and DNA fragmentation analysis also showed enhanced anti-TNBC effects. Investigation found that HCE acts via suppression of mitochondrial membrane potential and inducing caspase-3 activity in cells. Conclusion: Our findings suggested that photo-empowered phytotherapy can be employed effectively and safely against TNBC.


  • 3<sup>2</sup> Factorial Design of O/W Nanoemulsions of Cholecalciferol Using Box–Behnken Model for Plaque Psoriasis
    Mukesh Chandra Sharma and Mukul Sharma
    EManuscript Technologies
    Aim: The aim of the study was to design O/W Nanoemulsion using Cholecalciferol in different ratios of surfactants with Box-Behnken design model using Design Expert version 12. Response surface methodology, Box-Behnken was most suited followed by 3 independent variables (A, B, C) and 9 different responses with 17 different batches. Various responses like pH, % drug content drug entrapment and % in vitro drug release at different time intervals comparable with independent variables with % predicted errors calculated with SD±5 values. Materials and Methods: Cholecalciferol used as model drug, SPAN 20, SPAN 80 used as surfactant and Soybean oil used as oil phase for making Nanoemulsion preparation for plaque psoriasis treatment prepared by probe sonication method. Results: The VIF values were 1.0-1.03 and Ri 2 range between 0.00-0.0058 means correlated with each-others were in range, showed statistically correct and chances of error is minimum shown in Table 1. The predicted pH 7.79±0.38, Drug entrapment 92.68±4.67 and % Drug content was found to be 92.5±6.08 while experimental values were 7.20±0.11, 95.32±0.76, 93.29±1.15%. The predicted values of in vitro drug release were 5.54±1.57, 13.98±2.19, 25.96±4.40, 47.14±3.18, 68.17±6.02, 80.36±4.39% while experimental values were 8.50±0.50, 16.54±2.30, 29.54±2.27, 42.20±1.10, 68.54±1.27, 79.64±2.35% at 10, 30,60,90,120,210 min respectively see Table 2. The p values was <0.0001. Conclusion: The model showed F -values were in the range 0.28-5.08 showed non-significant while p -values was 0.028 showed significant values followed quadratic model. This showed that the model is best suitable for optimization.

  • Novel applications of Cold Atmospheric Plasma for the treatment of Plaque Psoriasis
    Mukesh Chandra Sharma and Mukul Sharma
    A and V Publications
    Plasma is the fourth state of matter other than solid, liquid and gases. About 99 percent of mixture of free positive negative charges, neutral particles and photons. The plasma exists in two forms: hot plasma and cold plasma. Hot plasma is used in metallurgical operations while cold plasma is used in medical, skin psoriasis treatment, food agricultural, preservation and waste water treatment. Many clinical studies prove the effectiveness of cold plasma in dermatological disease management. Recent researches have established that combined use of cold plasma and nano-formulations is helpful in delivery of poorly water-soluble drugs. Plaque psoriasis is an autoimmune disorder in which silvery, thick, dead layer of skin shades off and cause inflammation, sometimes bleeding. It occurs in 3-4 percent of total world population. Scientific studies have proved that nano-scale particles permeate easily and interact with immune cells like lnterleukin-16, cytokines and TNF-alfa during inflammation and autoimmune disorders. As a result of which, thick layer of keratinocytes is produced and formation of TNF-alfa and interleukin is inhibited which are the causes of Plaque psoriasis. Since conventional medication has only been helpful in managing it, researches have been carried out using various techniques like phototherapy, use of UVA, UVB, IPL (Intense Pulsed Light), PDL (Pulsed Dye Light), LASER and low-level LASER light etc. but their excess exposure causes risk of skin cancer. Other therapies like use of nanometric Liposomes, Niosomes and their combination therapy are some novel clinical techniques for combating symptoms but are still in clinical trial. Since, Plasma therapy is non irritating and stops the triggering mechanism of inflammation, hence the use of nanotechnological topical formulation in combination with plasma therapy has the potential to become possible treatment of Plaque Psoriasis in future.

  • Recent Advances in Polymer-Based Nanomaterials for Non-Invasive Photothermal Therapy of Arthritis
    Muktika Tekade, Prashant Pingale, Rachna Gupta, Bhakti Pawar, Rakesh Kumar Tekade, and Mukesh Chandra Sharma
    MDPI AG
    To date, nanomaterials have been widely used for the treatment and diagnosis of rheumatoid arthritis. Amongst various nanomaterials, polymer-based nanomaterials are becoming increasingly popular in nanomedicine due to their functionalised fabrication and easy synthesis, making them biocompatible, cost-effective, biodegradable, and efficient nanocarriers for the delivery of drugs to a specific target cell. They act as photothermal reagents with high absorption in the near-infrared region that can transform near-infrared light into localised heat with fewer side effects, provide easier integration with existing therapies, and offer increased effectiveness. They have been combined with photothermal therapy to understand the chemical and physical activities behind the stimuli-responsiveness of polymer nanomaterials. In this review article, we provide detailed information regarding the recent advances in polymer nanomaterials for the non-invasive photothermal treatment of arthritis. The synergistic effect of polymer nanomaterials and photothermal therapy has enhanced the treatment and diagnosis of arthritis and reduced the side effects of drugs in the joint cavity. In addition, further novel challenges and future perspectives must be resolved to advance polymer nanomaterials for the photothermal therapy of arthritis.

  • Detailed review on phytosomal formulation attenuating new pharmacological therapies
    Jyotsana Dwivedi, Pranjal Sachan, Pranay Wal, Sumeet Dwivedi, Mukesh Chandra Sharma, and Surada Prakash Rao
    Springer Science and Business Media LLC

  • Clinical detoxification of the body from chemical toxicants
    Muktika Tekade, Prashant L. Pingale, Sakshi P. Wani, Kuldeep Rajpoot, Nagaraja Sreeharsha, Mrudul Deshpande, Rakesh Kumar Tekade, and Mukesh C. Sharma
    Elsevier

  • Designing of novel nanoemulsions of retinol using box Behnken design for psoriasis
    Mukul Sharma, Mukesh Chandra Sharma, Rakhi Khabiya, Akanksha Dwivedi, Alankar Shrivastava, G.P. Choudhary, Shivani Dubey, and Sanjay Jain
    Elsevier BV


  • 2D QSAR STUDIES OF NOVEL TRIAZOLINONE DERIVATIVES AS ANGIOTENSIN II ANTAGONISTS USING TOPOLOGICAL DESCRIPTORS
    Mukesh C. Sharma, , and D. V. Kohli
    Indian Drug Manufacturers' Association (IDMA)
    Quantitative Structure Activity Relationship (QSAR) model on a series of triazolinone derivatives acting as angiotensin II receptor using partial least squares regression analysis was performed to compute the relationship with 2D structure descriptors. The computational studies were performed with trial version V-life Molecular Design Suite software. The developed models were validated using an internal predictive power and predictivity for the external test set of 0.8653, and 0.7981 were obtained. The F test value shows the overall statistical significance level. Models developed in this study have potential application in the prediction of binding affinity for the newly synthesized compounds.

  • Emerging role of novel excipients in drug product development and their safety concerns
    Suryanarayana Polaka, Bhakti Pawar, Muktika Tekade, Rutuja Satvase, Aparna Lakshmi Manchikalapudi, Mukesh Chandra Sharma, Vikas Pandey, Aditya Narayan Jhariya, and Rakesh Kumar Tekade
    Elsevier

  • Understanding the concept of signal toxicity and its implications on human health
    Muktika Tekade, HariPriya Koppisetti, Mukesh Chandra Sharma, Kuldeep Rajpoot, Pinaki Sengupta, Manoj Kumar, and Rakesh Kumar Tekade
    Elsevier

  • Zebrafish models for toxicological screening
    Suryanarayana Polaka, HariPriya Koppisetti, Shreya Pande, Muktika Tekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier

  • Pharmaceutical excipients: Special focus on adverse interactions
    Suryanarayana Polaka, Shyam Sudhakar Gomte, Vikas Pandey, Jai Divya Tella, Muktika Tekade, Mukesh Chandra Sharma, Nagashekhara Molugulu, and Rakesh Kumar Tekade
    Elsevier

  • Clinical importance of herb-drug interaction
    Suryanarayana Polaka, Sayali Chaudhari, Muktika Tekade, Mukesh Chandra Sharma, Neelesh Malviya, Sapna Malviya, and Rakesh Kumar Tekade
    Elsevier

  • Factors influencing drug toxicity
    Rachna Gupta, Kuldeep Rajpoot, Muktika Tekade, Mukesh Chandra Sharma, Maliheh Safavi, and Rakesh Kumar Tekade
    Elsevier

  • Molecular biology of apoptotic, necrotic, and necroptotic cell death
    Suryanarayana Polaka, Hari Priya Koppisetti, Rutuja Satvase, Aparna Lakshmi Manchikalapudi, Muktika Tekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier

  • Drug-drug interactions and their implications on the pharmacokinetics of the drugs
    Suryanarayana Polaka, Hari Priya Koppisetti, Muktika Tekade, Mukesh Chandra Sharma, Pinaki Sengupta, and Rakesh Kumar Tekade
    Elsevier

  • Importance of toxicity testing in drug discovery and research
    Rachna Gupta, Suryanarayana Polaka, Kuldeep Rajpoot, Muktika Tekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier

  • Toxicogenomics in drug safety assessment
    Suryanarayana Polaka, Nupur Vasdev, Sivaroopa Raji, Vaishali Makwana, Amarjitsing Rajput, Madhur Kulkarni, Muktika Tekade, Prashant Pingale, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier

  • Organ-on-chip for assessing environmental toxicants
    Suryanarayana Polaka, Priyanka Pulugu, Muktika Tekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier

  • In silico methods for the prediction of drug toxicity
    Kuldeep Rajpoot, Nimeet Desai, HariPriya Koppisetti, Muktika Tekade, Mukesh Chandra Sharma, Santosh Kumar Behera, and Rakesh Kumar Tekade
    Elsevier

  • Impact of ageing on the pharmacokinetics and pharmacodynamics of the drugs
    Suryanarayana Polaka, Jai Divya Tella, Muktika Tekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade
    Elsevier